Introduction
Inactivation of prostaglandin E2 (PGE2) passing through the pulmonary circulation comprises two distinct steps, uptake of substrate from the extracellular space and subsequent metabolism by intracellular enzymes, most significantly 15-hydroxy-prostaglandin dehydrogenase (PGDH). Inhibitors of the uptake process, for instance, bromcresol green and other indicator dyes (Bito & Baroody, 1975; Bakhle, Jancar & Whittle, 1978) and di-phloretin phosphate (Crutchley & Piper, 1975; Bakhle et al., 1978) have been described and so have inhibitors of the enzyme PGDH such as frusemide, caffeine and N-ethyl maleimide (Hansen, 1976) . It seemed reasonable to assume that, for analogues of PGE2 that are substrates for the uptake process but not for the enzyme PGDH, inactivation in the pulmonary circulation would not be affected by inhibitors of PGDH. As the experiments described below show, this and other assumptions were not justified.
Methods
Lungs were removed from male rats, anaesthetized with pentobarbitone (administered intraperitoneally), and perfused via the pulmonary artery with warmed (37°C), gassed (95%0 2 and 5% C02) Krebs solution at 8 ml/min as described previously (Alabaster & 0007-1188/79/040635-05 $01.00 Bakhle, 1970) . For bioassay the effluent superfused two strips of hamster stomach (Ubatuba, 1973) or rat stomach (Vane, 1957) attached to isotonic Harvard transducers and the contractions of these assay tissues were displayed on a Watanabe potentiometric pen recorder. Injections of prostaglandins (0.05 to 0.2 ml) were made into the pulmonary artery cannula ('al') or below the lung to pass directly over the assay tissues ('dir'). Inactivation was measured as described earlier (Bakhle et al., 1978) . In each experiment control inactivation was measured before the inhibitors were infused and their effects on inactivation determined.
In 
Results
Inhibition of prostaglandin E2 and 16, 16-dimethyl PGE2 inactivation Four compounds, described as inhibitors of PGDH in vitro, were tested for inhibition of the inactivation of PGE2 in rat isolated lung. As shown in Table 1 , all but caffeine were inhibitors in the perfused lung. In two experiments, the effect of one inhibitor of prostaglandin inactivation, frusemide, was confirmed radiochemically by adding [14C]-PGE2 to the unlabelled PGE2 used in bioassay. Lung effluent was collected for 10 min during an assay of PGE2 inactivation. Effluent was extracted and the extract analysed for PGE2 and metabolites by thin layer chromatography. The radioactivity associated with PGE2 and its metabolites was measured. When the PGE2 was given directly over the tissues ('dir'), 84% of the radioactivity co-chromatographed with the PGE2 marker. Injected into the pulmonary circulation ('al'), only 12% of the radioactivity was PGE2 and 84% chromatographed as the 15-oxo derivatives. Frusemide (10'3 M), infused through the lung, reduced the proportion of 15-oxo-PGE2 to 29% and the proportion of unchanged PGE2 was increased to 62%.
The inactivation of 16, 16-dimethyl PGE2 was also inhibited by the three compounds affecting PGE2 inactivation, whereas caffeine was again without effect (Table 1) . These experiments were carried out by bioassay and the effect of frusemide on the inactivation of 16, 16-dimethyl PGE2 is illustrated in Figure 1 . The slow onset of the contraction of the hamster stomach strip to the methyl analogue injected 'al' (third contraction) is typical of this analogue (Bakhle et al., 1978) . However, after frusemide, the contraction to the 'al' injection was rapid in onset and of greater magnitude, showing inhibition of inactivation. 16,10-dimethyl PGE2 60 + 6(6)l 67 + 3 (7) 16 + 2(8) 44 + 6 (7) 6 (2) 6 + 5 (6) 33 + 7(6) 37 + 8 (3) 56 + 13 (6) 11 + 8 (6) ' 
Number of experiments
All the values shown with the exception of those for caffeine represent a significant effect (P < 0.05; t test). degree of inhibition between these two substrates, which probably reflect the relative affinities of the uptake system for each substrate and for the inhibitors. Such differences have been observed before (Bakhle et al., 1978) . These results suggested that PGDH inhibitors were acting on the uptake process for prostaglandins. The second assumption was that, by analogy with 5-hydroxytryptamine, inhibition of the intracellular enzyme would enable substrate to accumulate unchanged in the lung and appear slowly in the effluent after the bolus had passed (Alabaster & Bakhle, 1970) . This would, for instance, lead to a slower washout of radioactivity from the lung following injection of ["4C]-PGE2 in the presence of PGDH inhibitors. The converse of this effect had already been reported, i.e. the more rapid washout of radioactivity derived from 14C-PGF2: in rat lung during infusion of the uptake inhibitor, bromcresol green (Bito & Baroody, 1975) . To was also reduced in the experiment described here i.e. the rate of radioactivity washout was increased in the experiments with bromcresol green. Although frusemide and N-ethyl maleimide were expected to produce a slower efflux of radioactivity and thus to increase To, they in fact reduced To to almost the same value as observed after bromcresol green. Thus, both sets of experiments, bioassay and radiochemical, led to the same unexpected conclusion that PGDH inhibitors prevented prostaglandin inactivation in perfused lung by preventing uptake rather than metabolism.
One explanation of these results would be to postulate that the uptake process for PGE2 is not capable of functioning against the increased concentration gradient caused by the increased intracellular level of prostaglandin consequent on PGDH inhibition. This explanation is unlikely because, as Anderson & Eling (1976) have shown, PGE inactivation in rat lung is controlled by PGDH activity rather than by the uptake of substrate. Indeed, they suggest that prostaglandin can be taken up and, if PGDH is saturated, be returned unchanged to the perfusate. Further evidence against this explanation is the effect on the methyl analogue which, as it is not a substrate for PGDH, cannot be affected by PGDH inhibitors alone.
An alternative explanation is to accept that some' inhibitors of PGDH are also inhibitors and, perhaps more potent inhibitors, of the uptake process for prostaglandins in lung. This dual action is not without precedent as di-phloretin phosphate (DPP) prevented metabolism of PGE2 by homogenates of guinea-pig lung (Crutchley & Piper, 1974) and also inhibited inactivation of 16, 16-dimethyl PGE2 (Bakhle et al., 1978) , thus showing an action on both PGDH and on uptake.
However, it could be argued that the highly ionized DPP molecule could not enter the cell to inhibit PGDH and thus its effects must be exerted at the cell surface. This argument cannot apply to frusemide nor to the recent experiments with probenecid (Bito, Baroody & Reitz, 1977) . In the latter work (published while this paper was in preparation) probenecid, an inhibitor of PGF2c, metabolism in homogenates and perfused lung, reduced the To for [3H]-PGF2<, in rat lung to the same value as the To for ["4C]-sucrose. Similar effects were produced by DPP and BCG. Thus, for PGF22 also it seems that inhibition of metabolism in perfused lung may be due more to inhibition of uptake than to inhibition of PGDH.
Although these experiments were designed to study the effects of PGDH inhibition on prostaglandin inactivation, they have, in fact, provided more information about the uptake process. For instance, this uptake process seems to have two chemically distinct groups of inhibitors, the highly ionised organic molecules like bromcresol green and other indicator dyes and di-phloretin phosphate, and those, less polar, compounds capable of reacting with sulphydryl groups like frusemide and N-ethyl maleimide. Other sulphydryl-reactive compounds which are inhibitors of prostaglandin inactivation, like ethacrynic acid and p-chloro-mercuribenzoate (Crutchley & Piper, 1974) may also act by blocking uptake in the perfused lung although they are known to inhibit PGDH in vitro. The two classes of inhibitor should help to define further the chemical features of the uptake system for prostaglandins in lung.
The effect of PGDH inhibition on inactivation in whole lung still remains to be determined and it may be that with a different type of PGDH inhibitor, lacking an effect on uptake, the two original assumptions would be justified. It is nevertheless interesting that, in the presence of inhibitors, the uptake step seems to be more readily affected and becomes rate-limiting whereas under normal conditions, the rate of PGE inactivation is limited by PGDH action and not by uptake (Anderson & Eling, 1976) . This and previous work (Bakhle et al., 1978) suggest also that 16,16-dimethyl PGE2 could be used as a means of investigating the prostaglandin uptake processes as distinct from prostaglandin metabolism by PGDH in lung or in other tissues. Finally, the present experiments re-emphasize the importance of uptake processes, under normal conditions or after drug treatment, as determinants of the fate of vasoactive hormones in the lung.
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